Swiss

Unlock Digest Editor free

Halef’s roller, FT editor chooses his favorite stories in this weekly newsletter.

Swiss Pharma Group Novartis said it will expand its production and research and development in the US $ 23 billion over five years, as drug manufacturers are erupting their supply networks in preparation for potential tariffs in the US.

Novartis, which makes a wide range of drugs from cancer to cardiovascular drugs, said the investment will allow it to produce all her key drugs in the US in the country. It will build seven new facilities and expand others.

You Naromshaan, Executive Director of the company NovartisHe said the investment reflects “the policy as a result of innovation and the normative environment in the US, which supports our ability to find the following medical breakthroughs for patients.”

The announcement is the latest American investment of a major drug company since Donald Trump has won the presidential election. Announced by Eli Lily, founded in Indianapolis, Eli Lily Investment plans for $ 27 billion In February, while Johnson & Johnson, which is with the Kwateer headquarters in New Jersey, stated last month that the deposit of more than $ 55 billion to four factories. In November, Astrazeneca said $ 3.5 billion in the US.

A the pharmaceutical industry was released from the wide global tariffs announced by Trump last week. But the administration said they would soon be imposed.

Novartis estimates that the investment will create nearly 1000 jobs in the company, and 4,000 in the supply chain and communities. It also invests in the production of active pharmaceutical ingredients in the US, in the region where the industry is very dependent on supplies from China and India.

The company will install the Institute of Research and Development of $ 1.1 billion in San Diego, the second in the US after the existing facility in the Boston area. It will open production facilities for X -ray therapy, innovative cancer treatment, which is a more focused version of radiation therapy, in Florida and Texas, and expand factories that are already treated in Indiana, New Jersey and California.

Naromsaman stated that the company was “prepared for shifts in the external setting” and “quite confident” in its recommendations for the year, and in the middle and long term, including its main margin leadership at least 40 percent by 2027.